1stOncology™: Cancer Intelligence Service – Page 100 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Soley Therapeutics Announces $200 Million Series C Financing to Propel Lead Oncology Programs into the Clinic and Scale Its Cell Stress Sensing Platform

On January 7, 2026 Soley Therapeutics ("Soley") reported a $200 million Series C financing to advance its proprietary cell stress sensing platform and pipeline of novel therapeutics into the clinic. Proceeds will support IND-enabling work and clinical trials for two first-in-class internally discovered and developed oncology assets, in addition to advancement of the non-oncology stress-reducing drug candidates for neurodegenerative disorders and metabolic diseases, and continued platform scale-up.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

New investors in this round included Surveyor Capital as primary investor, joined by HRTG Partners, RWN Management, and others. Existing Soley investors, including Doug Leone Family Fund, Breyer Capital, and GordonMD Global Investments LP, and other undisclosed investors also participated.

The Soley platform captures time-resolved responses across thousands of features in human cells, then uses proprietary computer vision and AI to convert those features into compact, structured signatures. It screens hundreds of thousands of compounds per week, generates reproducible data at scale in-house using first-in-class automation and robotics, and trains proprietary AI/ML models, to accelerate hit finding, mechanistic insights, and molecule design.

"We built Soley to measure how living human cells, in health and disease, respond to drug exposure and determine their fate. We then translate this cellular information into a robust portfolio of novel drug candidates across a broad range of disease areas and indications," said Yerem Yeghiazarians, M.D., Co-founder and CEO of Soley Therapeutics. "We are thrilled by the strong investor support from life sciences and technology focused funds as we advance our lead programs into the clinic and expand our platform to continue building a first-in-class pipeline."

(Press release, Soley Therapeutics, JAN 7, 2026, View Source [SID1234661813])

Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

On January 7, 2026 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, reported that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Wednesday, January 14, 2026. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

The webcast will be accessible on the Investor Relations page of Sana’s website at View Source A replay of the presentation will be available at the same location for 30 days following the conference.

(Press release, Sana Biotechnology, JAN 7, 2026, View Source [SID1234661812])

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

On January 7, 2026 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, reported that Raul Rodriguez, the company’s president and CEO, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 3:00 p.m. PT (6:00 p.m. ET).

To access the live webcast or archived recording, visit the Investor Relations section of the company’s website at www.rigel.com. Please connect to Rigel’s website prior to the start of the live webcast to allow for any software downloads.

(Press release, Rigel, JAN 7, 2026, View Source [SID1234661811])

RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

On January 7, 2026 RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, reported that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 44thAnnual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific Time.

To access the live webcast or subsequent archived recording of the presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

(Press release, RAPT Therapeutics, JAN 7, 2026, https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-present-44th-annual-jp-morgan-healthcare [SID1234661810])

Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240

On January 7, 2026 Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, reported successful completion of a non-human primates toxicology study (the "Study") of IM1240, a tri-specific antibody from its CAPTN-3 platform that targets 5T4, a tumor-specific antigen expressed on multiple solid tumors.

The Study demonstrated that IM1240’s proprietary capping technology enabled dosing at levels up to 300-fold higher than a non-capped comparator, with significantly reduced immune-related toxicity, including minimal cytokine release. These results highlight the unique safety profile of this approach, which may address a key limitation of certain current T cell engagers, where cytokine release syndrome can restrict dosing.

"In the Study, IM1240 demonstrated a favorable safety and tolerability profile, with hematologic findings that align with its expected pharmacodynamic effects on immune activation. The CD3 capping design of IM1240 showed clear differentiation compared with the non-capped comparator, IM1222, enabling a significant reduction in immune-related effects, including cytokine release, which remained modest, even at doses up to 300-fold higher than those of the non-capped antibody," stated Gil Efron, CEO of Purple Biotech. "Purple Biotech continues to deliver on its stated milestones and we believe that collectively, these data provide translational guidance that may inform optimal dose selection, dosing strategy, and safety monitoring plans for the next phase of advanced toxicological assessments. We are working to advance IM1240 toward first-in-human studies as efficiently as possible and expect to provide updates on our progress over the course of 2026."

IM1240 demonstrated a favorable pharmacokinetic (PK) profile in the Study, characterized by increased systemic exposure and a prolonged circulating half-life. PK analyses showed dose-dependent and proportional increases in exposure, as reflected by both AUC and Cmax. The Company believes these findings support dose-exposure relationship and provide proof of concept for the capping design and albumin incorporation as a contributor to IM1240’s favorable PK profile. In addition, efficacy observed in vivo in tumor-bearing mice occurred at exposures meaningfully lower than those achieved in the Study, further supporting IM1240’s advantageous therapeutic window.

About the CAPTN-3 Platform

CAPTN-3, Purple Biotech’s lead program, is a platform of capped tri-specific antibodies that simultaneously target tumor-associated antigens while engaging both T cells and NK cells. Proprietary capping technology confines immune activation to the tumor microenvironment by masking the CD3-binding arm in circulation and activating it only at the tumor site, significantly expanding the therapeutic window versus conventional T-cell engagers. The platform’s lead candidates, IM1240 (targeting 5T4) and IM1305 (targeting TROP2), are in preclinical development.

(Press release, Purple Biotech, JAN 7, 2026, View Source [SID1234661809])